Literature DB >> 7031100

Chenodeoxycholic acid and ursodeoxycholic acid effects in endogenous hypertriglyceridemias. A controlled double-blind trial.

N Carulli, M Ponz de Leon, M Podda, M Zuin, A Strata, G Frigerio, A Digrisolo.   

Abstract

A double-blind controlled trial was carried out to compare the effects of chenodeoxycholic acid (CDCA), ursodeoxycholic acid (UDCA), and placebo on cholesterol and triglyceride levels in patients with endogenous hypertriglyceridemias. The dose of both bile acids was four 150-mg capsules day. Total serum cholesterol levels did not show appreciable changes with any of the treatments. HDL cholesterol was significantly increased after CDCA but not after UDCA or placebo. CDCA feeding was associated with a significant decrease in serum triglyceride levels, whereas the other treatments failed to show an effect. It is concluded that UDCA does not affect serum lipid levels, whereas CDCA lowers serum triglycerides and may be useful in the treatment of endogenous hypertriglyceridemia.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7031100     DOI: 10.1002/j.1552-4604.1981.tb01746.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  13 in total

Review 1.  New perspectives for the treatment of cholestasis: lessons from basic science applied clinically.

Authors:  James L Boyer
Journal:  J Hepatol       Date:  2006-12-18       Impact factor: 25.083

2.  alpha(1)-fetoprotein transcription factor (FTF)/liver receptor homolog-1 (LRH-1) is an essential lipogenic regulator.

Authors:  Zhumei Xu; Lingli Ouyang; Antonio Del Castillo-Olivares; William M Pandak; Gregorio Gil
Journal:  Biochim Biophys Acta       Date:  2009-12-28

Review 3.  Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II.

Authors:  W H Bachrach; A F Hofmann
Journal:  Dig Dis Sci       Date:  1982-09       Impact factor: 3.199

Review 4.  Pathogenesis of alcoholic liver disease: the role of nuclear receptors.

Authors:  Maxwell Afari Gyamfi; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2010-05

5.  Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial.

Authors:  Zahid Ahmad; Lalitha Subramanyam; Lidia Szczepaniak; Vinaya Simha; Beverley Adams-Huet; Abhimanyu Garg
Journal:  Eur J Endocrinol       Date:  2013-04-15       Impact factor: 6.664

6.  Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c.

Authors:  Mitsuhiro Watanabe; Sander M Houten; Li Wang; Antonio Moschetta; David J Mangelsdorf; Richard A Heyman; David D Moore; Johan Auwerx
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

7.  Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype.

Authors:  Clive R Pullinger; Celeste Eng; Gerald Salen; Sarah Shefer; Ashok K Batta; Sandra K Erickson; Andrea Verhagen; Christopher R Rivera; Sean J Mulvihill; Mary J Malloy; John P Kane
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 8.  Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy.

Authors:  A Ward; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-02       Impact factor: 9.546

Review 9.  Endocrine and paracrine role of bile acids.

Authors:  Verena Keitel; Ralf Kubitz; Dieter Häussinger
Journal:  World J Gastroenterol       Date:  2008-10-07       Impact factor: 5.742

10.  ANGPTL4 is produced by entero-endocrine cells in the human intestinal tract.

Authors:  Sheril Alex; Laeticia Lichtenstein; Wieneke Dijk; Ronald P Mensink; Nguan Soon Tan; Sander Kersten
Journal:  Histochem Cell Biol       Date:  2013-10-19       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.